Intravitreal aflibercept injection vs sham as prophylaxis against conversion to exudative age-related macular degeneration in high-risk eyes: a randomized clinical trial
Importance Anti–vascular endothelial growth factor (VEGF) agents may provide a
prophylactic effect in high-risk eyes with intermediate dry age-related macular degeneration
(AMD) against conversion to exudative AMD (eAMD), lowering the risk of vision loss.
Objective To evaluate intravitreal aflibercept injection (IAI) as prophylaxis against the
conversion to eAMD in high-risk eyes at 24 months. Design, Setting, and Participants This
single-masked, sham-controlled, randomized clinical trial performed at 4 US clinical sites …
prophylactic effect in high-risk eyes with intermediate dry age-related macular degeneration
(AMD) against conversion to exudative AMD (eAMD), lowering the risk of vision loss.
Objective To evaluate intravitreal aflibercept injection (IAI) as prophylaxis against the
conversion to eAMD in high-risk eyes at 24 months. Design, Setting, and Participants This
single-masked, sham-controlled, randomized clinical trial performed at 4 US clinical sites …
